AN2 Therapeutics, Inc.
$3.62
▼
-5.22%
2026-04-21 05:19:00
www.an2therapeutics.com
NMS: ANTX
Explore AN2 Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$129.78 M
Current Price
$3.62
52W High / Low
$6.91 / $1
Stock P/E
—
Book Value
$1.94
Dividend Yield
—
ROCE
-71.59%
ROE
-52.14%
Face Value
—
EPS
$-1.16
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
21
Beta
-1.32
Debt / Equity
—
Current Ratio
6.87
Quick Ratio
6.87
Forward P/E
-3.71
Price / Sales
—
Enterprise Value
$48.74 M
EV / EBITDA
—
EV / Revenue
—
Rating
None
Target Price
$1
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Pasithea Therapeutics Corp. | $0.72 | — | $18.52 M | — | -37.74% | -58.36% | $3.79 / $0.28 | $2.39 |
| 2. | Dyadic International, Inc. | $0.88 | — | $31.88 M | — | -114.18% | -3.98% | $1.35 / $0.65 | $0.03 |
| 3. | OSR Holdings, Inc. | $0.6 | — | $19.87 M | — | 79.82% | -20.03% | $1.79 / $0.38 | $3.46 |
| 4. | Anavex Life Sciences Corp. | $3.65 | — | $338.25 M | — | -54.15% | -33.63% | $13.99 / $2.61 | $1.37 |
| 5. | CalciMedica, Inc. | $0.66 | — | $9.49 M | — | -235.71% | -7.61% | $7.2 / $0.46 | $-0.43 |
| 6. | Ultragenyx Pharmaceutical Inc. | $25.06 | — | $2.39 B | — | -46.6% | -6.08% | $42.37 / $18.29 | $-0.83 |
| 7. | ProQR Therapeutics N.V. | $1.84 | — | $206.51 M | — | -54.09% | -61.17% | $3.1 / $1.1 | $0.54 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -9.32 M | -10.04 M | -7.22 M | -11.54 M | -8.61 M | — |
| Net Profit | -8.71 M | -9.35 M | -6.46 M | -10.65 M | -7.52 M | — |
| EPS in Rs | -0.24 | -0.26 | -0.18 | -0.3 | -0.21 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -38.11 M | -54.55 M | -69.64 M | -42.26 M |
| Net Profit | -35.17 M | -51.32 M | -64.73 M | -40.96 M |
| EPS in Rs | -0.98 | -1.43 | -1.8 | -1.14 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 61.95 M | 92.09 M | 138.74 M | 102.56 M |
| Total Liabilities | 8.89 M | 10.24 M | 14.04 M | 7.19 M |
| Equity | 53.06 M | 81.85 M | 124.7 M | 95.37 M |
| Current Assets | 59.94 M | 86.26 M | 110.51 M | 98.62 M |
| Current Liabilities | 8.72 M | 10.24 M | 14.04 M | 7.19 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -29.83 M | -49.26 M | -53.29 M | -33.46 M |
| Investing CF | 28.31 M | 54.59 M | -43.28 M | -21.77 M |
| Financing CF | 0.11 M | 0.37 M | 84.99 M | 70.36 M |
| Free CF | -29.83 M | -49.26 M | -53.29 M | -33.46 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 20.72% | -58.05% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.